| Description |
Recombinant Mouse EREG Protein is expressed from HEK293 with hFc tag at the N-Terminus.It contains Val56-Leu101. |
| Purity |
> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
| Accession |
Q61521 |
| Target Symbol |
EREG |
| Synonyms |
Proepiregulin; EPR; Epiregulin; EREG; ER |
| Species |
Mouse |
| Expression System |
HEK293 |
| Tag |
N-hFc |
| Expression Range |
Val56-Leu101 |
| Mol. Weight |
The protein has a predicted MW of 32.7 kDa. Due to glycosylation, the protein migrates to 37-40 kDa based on Tris-Bis PAGE result. |
| Form |
Lyophilized |
| Formulation |
Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Endotoxin |
Less than 1EU per ug by the LAL method. |
| Storage |
Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
| Shipping |
Shipped at ambient temperature. |
| Gene Background |
Epidermal growth factor receptor (EGFR) regulates many crucial cellular programs, with seven different activating ligands shaping cell signaling in distinct ways.EGFR ligands epiregulin (EREG) and epigen (EPGN) stabilize different dimeric conformations of the EGFR extracellular region. As a consequence, EREG or EPGN induce less stable EGFR dimers than EGF-making them partial agonists of EGFR dimerization. Unexpectedly, this weakened dimerization elicits more sustained EGFR signaling than seen with EGF, provoking responses in breast cancer cells associated with differentiation rather than proliferation. |
